Marc Casper Sells 400 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Key Points

• Thermo Fisher Scientific CEO Marc Casper sold 400 shares of the company's stock for a total of $200,200, decreasing his ownership by 0.35% while still retaining 113,762 shares.
• The company reported quarterly earnings of $5.36 per share, surpassing analyst expectations, with revenue of $10.86 billion, reflecting a 2.9% increase year-over-year.
• Thermo Fisher Scientific's recent quarterly dividend of $0.43 will be paid on October 15th, marking an annualized yield of 0.4% and a dividend payout ratio of 9.95%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc Casper sold 400 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $3.85 during mid-day trading on Tuesday, reaching $483.80. The company had a trading volume of 1,501,640 shares, compared to its average volume of 2,414,667. The company's 50 day simple moving average is $462.34 and its 200 day simple moving average is $451.98. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $182.69 billion, a price-to-earnings ratio of 27.98, a P/E/G ratio of 2.63 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Barclays raised their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a report on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $589.38.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. NWF Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $377,000. Reynders McVeigh Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.5% in the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 9,710 shares of the medical research company's stock valued at $3,937,000 after acquiring an additional 45 shares in the last quarter. SevenBridge Financial Group LLC increased its stake in shares of Thermo Fisher Scientific by 38.3% in the 2nd quarter. SevenBridge Financial Group LLC now owns 4,955 shares of the medical research company's stock valued at $2,009,000 after acquiring an additional 1,371 shares in the last quarter. Osaic Holdings Inc. increased its stake in shares of Thermo Fisher Scientific by 35.7% in the 2nd quarter. Osaic Holdings Inc. now owns 67,715 shares of the medical research company's stock valued at $28,572,000 after acquiring an additional 17,806 shares in the last quarter. Finally, American Trust increased its stake in shares of Thermo Fisher Scientific by 1.7% in the 2nd quarter. American Trust now owns 5,663 shares of the medical research company's stock valued at $2,296,000 after acquiring an additional 93 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.